Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma—A Real-World Multicenter Study (RICE-Retro)

Overview of attention for article published in Frontiers in immunology, July 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 11 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 13 publications that cite this research output.

13

The most recent citing publications are shown below. View all 13 publications that cite this research output on Dimensions.

Conversion chemoradiotherapy combined with nab-paclitaxel plus cisplatin in patients with locally advanced borderline-resectable or unresectable esophageal squamous cell carcinoma: a phase i/ii prospective cohort study

Article in Strahlentherapie und Onkologie (August 2024)

Preoperative camrelizumab combined with chemotherapy for borderline resectable ESCC: A single-arm, prospective, phase 2 study

Article in Med (July 2024)

Neoadjuvant immunochemotherapy improves clinical outcomes of patients with esophageal cancer by mediating anti-tumor immunity of CD8+ T (Tc1) and CD16+ NK cells

Article in Frontiers in Immunology (July 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.